EL-PHASE3-CHINA

Regimen

Experimental
Lobaplatin 30 mg/m2 d1 + etoposide 100 mg/m2 d1-3 q21d (EL)
Control
Cisplatin 80 mg/m2 d1 + etoposide 100 mg/m2 d1-3 q21d (EP)

Population

Previously untreated extensive-stage SCLC, enrolled at 17 sites in China Sep 2010 - May 2013

Key finding

mPFS 5.1 vs 5.3 mo (P=0.786); mOS 10.6 vs 9.7 mo (P=0.701); DCR 85.5% vs 86.7% (P=0.848); EL had lower nephrotoxicity (2.5% vs 11.7%, P=0.008) and GI toxicity

Source: PMID 30988825

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.63)⚠️ OCR source